Tan Pham, MD
Endocrinology, Diabetes & Metabolism · Norman, OKNPI 1740259076
Payments from drug & device makers
Across 391 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$874
- Tandem Diabetes Care, Inc.$729
- Sanofi-aventis U.S. LLC$362
- Dexcom, Inc.$326
- Xeris Pharmaceuticals, Inc.$326
- plus $4K from 39 others
What the payments were for
- Speaking & faculty fees$4256%
- Food & beverage$6,95794%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,421 in reported general payments places this provider in the 65th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 208 | $357,131 |
| MounjaroTirzepatide | 147 | $200,479 |
| JardianceEmpagliflozin | 148 | $173,231 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $137,285 |
| FarxigaDapagliflozin Propanediol | 105 | $123,443 |
| TrulicityDulaglutide | 35 | $50,325 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $35,556 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $31,819 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $29,892 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $29,463 |
| ProliaDenosumab | 15 | $25,599 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $20,364 |
| SynthroidLevothyroxine Sodium | 165 | $16,064 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $15,770 |
| Cinacalcet Hcl | 33 | $13,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $874 | $357,131208 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,041 | $253,906200 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr, Tradjenta | $77 | $214,487196 claims |
| AstraZenecaFarxiga | $315 | $123,443105 claims |
| AmgenProlia | $265 | $25,59915 claims |
| AbbVieSynthroid | $172 | $16,064165 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $11,439989 claims |
| Johnson & JohnsonInvokana | $256 | $7,76313 claims |
| Sanofi-aventis U.S. LLCLantus | $362 | $4,01714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Norman
- Lubna MirzaNorman$837K
- Shelley McClureNorman$3K
- Cassie SmithEdmond$629K
- Matthew DraelosEdmond$392K
- Robert ScofieldOklahoma City$189K
- Jonea LimOklahoma City$172K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Christian MangrumOklahoma City$54K
- Elie AbedTulsa$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.